Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 39kWORD 9k
17 January 2020
Question for written answer E-000263/2020
to the Commission
Rule 138
Joanna Kopcińska (ECR)
 Answer in writing 
 Subject: Poor access to medicines in the EU

Europe has recently been struggling with a lack of access to medicines. This problem is not limited to specialist or complex medicinal products: the most basic medical supplies can also be hard to come by, not only in the countries in the east of the EU, but also in highly developed countries with top-quality healthcare.

There is no question that one of the main reasons for poor access to medicines is that the active substances required are mostly produced in factories in Asia, namely China and India.

It has been clear for years now that the best solution would be to bring in regulatory measures to encourage manufacturers to return to Europe.

1. What action is the Commission intending to take to help ensure that the European pharmaceutical industry is given the right incentives to return to Europe, thereby guaranteeing the continent’s safety in terms of access to medicines?

2. Is the Commission intending to carry out a public consultation to meet the expectations of the European pharmaceutical industry and persuade it to return its operations to Europe, so as to ensure that patients once again have free and equal access to the medicines they need?

Original language of question: PL
Last updated: 25 September 2020Legal notice - Privacy policy